Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Molecules ; 29(12)2024 Jun 14.
Artigo em Inglês | MEDLINE | ID: mdl-38930897

RESUMO

This study investigated the mechanism by which fucoxanthin acts as a novel ferroptosis inducer to inhibit tongue cancer. The MTT assay was used to detect the inhibitory effects of fucoxanthin on SCC-25 human tongue squamous carcinoma cells. The levels of reactive oxygen species (ROS), mitochondrial membrane potential (MMP), glutathione (GSH), superoxide dismutase (SOD), malondialdehyde (MDA), and total iron were measured. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blotting were used to assess glutathione peroxidase 4 (GPX4), nuclear factor erythroid 2-related factor 2 (Nrf2), Keap1, solute carrier family 7 member 11 (SLC7A11), transferrin receptor protein 1 (TFR1), p53, and heme oxygenase 1 (HO-1) expression. Molecular docking was performed to validate interactions. Compared with the control group, the activity of fucoxanthin-treated SCC-25 cells significantly decreased in a dose- and time-dependent manner. The levels of MMP, GSH, and SOD significantly decreased in fucoxanthin-treated SCC-25 cells; the levels of ROS, MDA, and total iron significantly increased. mRNA and protein expression levels of Keap1, GPX4, Nrf2, and HO-1 in fucoxanthin-treated cells were significantly decreased, whereas levels of TFR1 and p53 were significantly increased, in a concentration-dependent manner. Molecular docking analysis revealed that binding free energies of fucoxanthin with p53, SLC7A11, GPX4, Nrf2, Keap1, HO-1, and TFR1 were below -5 kcal/mol, primarily based on active site hydrogen bonding. Our findings suggest that fucoxanthin can induce ferroptosis in SCC-25 cells, highlighting its potential as a treatment for tongue cancer.


Assuntos
Ferroptose , Heme Oxigenase-1 , Simulação de Acoplamento Molecular , Fator 2 Relacionado a NF-E2 , Fosfolipídeo Hidroperóxido Glutationa Peroxidase , Xantofilas , Humanos , Fator 2 Relacionado a NF-E2/metabolismo , Ferroptose/efeitos dos fármacos , Xantofilas/farmacologia , Xantofilas/química , Heme Oxigenase-1/metabolismo , Heme Oxigenase-1/genética , Linhagem Celular Tumoral , Fosfolipídeo Hidroperóxido Glutationa Peroxidase/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Transdução de Sinais/efeitos dos fármacos , Neoplasias da Língua/tratamento farmacológico , Neoplasias da Língua/metabolismo , Neoplasias da Língua/patologia , Receptores da Transferrina/metabolismo , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Proteína 1 Associada a ECH Semelhante a Kelch/metabolismo , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Sistema y+ de Transporte de Aminoácidos/metabolismo , Sistema y+ de Transporte de Aminoácidos/genética , Superóxido Dismutase/metabolismo , Regulação para Baixo/efeitos dos fármacos , Antígenos CD
2.
Mar Drugs ; 21(5)2023 May 08.
Artigo em Inglês | MEDLINE | ID: mdl-37233483

RESUMO

Studies have shown that Sargassum fusiforme and its extracts are effective herbal treatments for leukemia. We previously found that a polysaccharide from Sargassum fusiforme, SFP 2205, stimulated apoptosis in human erythroleukemia (HEL) cells. However, the structural characterization and antitumoral mechanisms of SFP 2205 remain uncertain. Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model. The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively. On animal assays, SFP 2205 significantly inhibited growth of HEL tumor xenografts with no discernible toxicity to normal tissues. Western blotting showed that SFP 2205 therapy improved Bad, Caspase-9, and Caspase-3 protein expression, and ultimately induced HEL tumor apoptosis, indicating mitochondrial pathway involvement. Furthermore, SFP 2205 blocked the PI3K/AKT signaling pathway and 740 Y-P, an activator of the PI3K/AKT pathway, rescued the effects of SFP 2205 on HEL cell proliferation and apoptosis. Overall, SFP 2205 may be a potential functional food additive or adjuvant for preventing or treating leukemia.


Assuntos
Leucemia , Neoplasias , Sargassum , Humanos , Camundongos , Animais , Proteínas Proto-Oncogênicas c-akt , Fosfatidilinositol 3-Quinases , Sargassum/química , Polissacarídeos/farmacologia , Polissacarídeos/química
3.
J Pharm Pharmacol ; 65(5): 673-81, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23600384

RESUMO

OBJECTIVES: Electrospun micro- and nanofibres are increasingly being investigated for drug delivery. The components of nanofibres are important influences on the drug release behaviour. The aim of this study was to investigate the self-assembly and release behaviour of drug from nanofibres. METHODS: Water-insoluble drug nifedipine (NIF)-loaded nanofibres with polymeric carrier of polycaprolactone (PCL)-based polyurethane (PU) were fabricated by electrospinning. The morphology of the nanofibres and the composite nanofibres with NIF were examined by scanning electron microscopy (SEM). The interactions between NIF and PU were followed by Fourier-transform infrared spectroscopy, and the elemental composition on the surface of the nanofibres was characterized by X-ray photoelectron spectroscopy. The release behaviour of NIF from nanofibres was observed by SEM (contacted with or without a drop of ethanol), and demonstrated by UV-Vis spectroscopy. KEY FINDINGS: In-vitro drug release studies revealed that a self-assembly process of NIF particles might be achieved within the body of the nanofibres. The electrospun nanofibre was an ideal drug carrier compared with a spin-coated film and could achieve controlled release of drug. CONCLUSIONS: The electrospinning technique could be used to fabricate a polymeric carrier that might have potential applications in the biomedical field.


Assuntos
Portadores de Fármacos/química , Nanofibras/química , Nifedipino/química , Poliésteres/química , Poliuretanos/química , Preparações de Ação Retardada
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...